Research & Development: Page 28

PharmaVoice Team/PharmaVoice

Letter from the Editor

The sequelae The personal, economic, and cultural upheaval from the coronavirus tragedy has changed our lives. The numbers, which during the early days of reported cases were abstract for most of us, have taken on new meaning in the subsequent months, as most of us now know someone who has contra...
By Taren Grom • May 1, 2020
PharmaVoice Team/PharmaVoice

Changing Health Outcomes with Digital Twins

While the digital twin is not yet widely used in the pharmaceutical industry, the concept has huge potential across R&D and manufacturing. A decades-old technology is coming of age in the life-sciences industry, bringing with it the potential to solve many of the challenges companies continue...
By Kim Ribbink • May 1, 2020
Explore the Trendline➔

Stock via Getty Images

Trendline

Clinical trial diversity

As pharma wises up to the fact that the current playbook for improving clinical trial diversity has yet to make a meaningful impact, the quest is on to refine that approach.
By PharmaVoice staff
PharmaVoice Team/PharmaVoice

Women of Influence

Leaders become great, not because of their power, but because of their ability to empower others – John Maxwell More than two dozen women who sit in seats of influence are using their talents, strategic acumen, and tenacity to create change throughout the life-sciences industry and their organiza...
By PharmaVoice Team • April 1, 2020
PharmaVoice Team/PharmaVoice

Upfront

Teva and Direct Relief Partner to Bring Cancer Medicines to Africa Global HOPE (Hematology-Oncology Pediatric Excellence), a program of Texas Children’s Hospital, Teva Pharmaceutical Industries, and Direct Relief are partnering to provide access to medications in sub-Saharan Africa, where a major...
By PharmaVoice Team • March 1, 2020
PharmaVoice Team/PharmaVoice

Patient-Enhanced Drug Discovery and Development

Patients are uniquely positioned to inform the understanding of the therapeutic context for drug development and evaluation. In other industries, it would seem odd not to get input from the end user of a product throughout the development stages. But it seems that pharmaceutical companies — some ...
By Taren Grom • March 1, 2020
PharmaVoice Team/PharmaVoice

Patient Relationships: Physicians and Payers

Patients are taking an active role in developing relationships with all stakeholders within their healthcare environment. Over the past several years, the relationship between pharma companies and patients has garnered much of the industry’s attention. But as patients become more empowered, engag...
By Robin Robinson • March 1, 2020
PharmaVoice Team/PharmaVoice

SHOWCASE: Real-World Evidence Comes of Age

Whether for product development, to support clinical trial designs, for regulatory compliance, or for commercial purposes, real-world data and real-world evidence are helping to transform pharmaceutical decision-making. The legal and regulatory environment is supportive of real-world data (RWD) a...
By PharmaVoice Team • March 1, 2020
PharmaVoice Team/PharmaVoice

Ask the Experts: How Does Real World Evidence Ensure Market Access?

Our healthcare system has experienced a fundamental shift in stakeholders’ perceptions of product value and evidentiary thresholds to demonstrate comparative effectiveness, as well as a willingness by relevant decision makers to pay. This value-and-evidence-based landscape is now relying heavily ...
By Laura Clark • March 1, 2020
PharmaVoice Team/PharmaVoice

RWE is the Future of Clinical Research: Time to Get Onboard

We’ve been talking about the value of real-world evidence (RWE) for years. A myriad of new data sources is being developed and linked, and a core set of analytic tools are coming into use. We now see real-world data running the gamut from patient-generated data collected through wearables and soc...
By Nancy A. Dreyer • March 1, 2020
PharmaVoice Team/PharmaVoice

A Different Kind of Real-World Evidence: The Key Role That Patient-Provider Dialogue Research Can Play

All roads in healthcare lead to and from the medical visit. Well, maybe not all roads, but nearly all. The medical visit is central to the overarching healthcare structure and it is driven by the dialogue between patient and provider. The healthcare data and research landscape has been changing s...
By Katy Hewett • March 1, 2020
PharmaVoice Team/PharmaVoice

Clinical Educators Provide Support Along the Whole Patient Journey

Team Power The teams of clinical educators at VMS BioMarketing are driven to help patients on a one-to-one basis to manage chronic illnesses — in the field or on the phone each day. Taking A Step-Wise Approach to clinical education There is one club that no one wants to join, but for those who wo...
By Clinical Educator Teams • March 1, 2020
PharmaVoice Team/PharmaVoice

Executive Perspective: What Clinical technology Can Learn from Electronic Health Records

The future of clinical technology encompasses both better adoption of simple solutions and a slower evolution toward new technologies with the focus on the patient at the center. Mike Nolte CEO, Signant Health Early in the adoption of electronic health records (EHRs), some technology leaders reco...
By Mike Nolte • March 1, 2020
PharmaVoice Team/PharmaVoice

Letter from the Editor

What’s old is new again This month’s cover story addresses an interesting take on science, or rather repurposing scientific R&D in a different way. For a whole host of reasons — patent cliffs, increasing discovery and development costs, mergers and acquisitions — companies are becoming more s...
By Taren Grom • Feb. 1, 2020
PharmaVoice Team/PharmaVoice

Innovator's Corner

A Potential Cure for Hepatitis B Dr. Lawrence Blatt, CEO, Aligos Therapeutics, discusses his company’s research around antisense oligonucleotides as potential therapies for chronic hepatitis B and other diseases of the liver. Despite an available vaccine, the incidence of chronic hepatitis B (HBV...
By PharmaVoice Team • Feb. 1, 2020
PharmaVoice Team/PharmaVoice

New Pipeline Pathways

The industry is becoming more strategic about repurposing its existing and shelved drugs. In the 1960s it became apparent that the drug thalidomide caused horrible birth defects in babies when pregnant mothers took it to treat their nausea. It was removed from the market. However today, that same...
By Robin Robinson • Feb. 1, 2020
PharmaVoice Team/PharmaVoice

SHOWCASE: Rare Disease: Rare But Not Scarce: The Struggle Faced By Millions

A single rare disease may afflict just a small number of people, but collectively up to 400 million people globally live with a rare disease. Exactly what is a rare disease? Collectively, rare isn’t scarce or infrequent. That’s the message that the organizers of Rare Disease Day 2020 are striving...
By PharmaVoice Team • Feb. 1, 2020
PharmaVoice Team/PharmaVoice

Lessons Learned from rare Disease First Commercial Launches

There’s nothing more exciting, and more nerve-wracking, than a new product launch — even more so when it’s a company’s first commercial launch. We’ve had the privilege of working on more than 10 first commercial launches, most of them in rare disease. As an agency partner we’ve worked with biotec...
By Annemarie Armstrong • Feb. 1, 2020
PharmaVoice Team/PharmaVoice

How the "Power of Why" Can Improve Adherence Rates in Rare Disease

Best-selling author and motivational speaker, Simon Sinek, is best known for his 2009 Ted Talk challenging organizations to set aside their list of product benefits and features to focus on the core purpose of their existence. He asks, WHY are you motivated to do what you do every day? Sinek sug...
By Kathi Hensen • Feb. 1, 2020
PharmaVoice Team/PharmaVoice

Finding Patients With Rare Diseases — Two Truths and a Lie

The hope for many companies developing drugs for rare diseases is this: the significant unmet need, given a dearth of treatment options, will drive demand and thus product uptake. Unfortunately, the reality is more challenging. While we have seen a significant increase in the number of drugs for ...
By Susan Abedi • Feb. 1, 2020
PharmaVoice Team/PharmaVoice

R&D INFLUENCER: Bert Hartog, Ph.D. — Janssen Pharmaceutical Companies of Johnson & Johnson

Unlocking clinical Bottlenecks We need to make more trials more accessible to more people. participate Bert Hartog, Ph.D., senior director at Janssen Clinical Innovation, Janssen Research & Development LLC is driven to eliminate the challenges preventing patients from participating in clinica...
By Bert Hartog • Feb. 1, 2020
PharmaVoice Team/PharmaVoice

R&D INFLUENCER: Jill Johnston — WCG, Clinical Services Organization

Breaking Down the Roadblocks to Site Activation My focus is on getting life-saving drugs to patients as quickly as possible by reducing the time it takes sites to enroll patients into trials. There’s a big difference between people with a vision and those who can execute on that idea. Jill Johnst...
By Jill Johnston • Feb. 1, 2020
PharmaVoice Team/PharmaVoice

Commanders & Chiefs: Innovators

Chief innovators provide their insights on what innovation means to them, keys to driving innovation, and what it takes to foster an innovation-driven company culture. Defining Innovation Garde. We define innovation as breaking business barriers through measurable and unique client-focused soluti...
By PharmaVoice Team • Feb. 1, 2020
PharmaVoice Team/PharmaVoice

Letter from the Editor

The Road Ahead As we head into 2020, closing out a decade punctuated by an ever-changing healthcare dynamic shaped by scientific discoveries, technological breakthroughs, innovation at every level, as well as global geopolitical forces, there is no doubt that the status quo is no longer a busines...
By Taren Grom • Jan. 1, 2020
PharmaVoice Team/PharmaVoice

Innovator's Corner

Fish Skin for Wounds Fertram Sigurjonsson, Founder and CEO of Kerecis, talks about his company’s skin-substitution technology, which comes from Icelandic cod. Fertram Sigurjonsson started Kerecis because he wanted to help people avoid life-altering amputations, which often result from hard-to-hea...
By Fertram Sigurjonsson • Jan. 1, 2020
PharmaVoice Team/PharmaVoice

Last Word

Creating an Innovative Culture Fabrice Chouraqui, former president of Novartis Pharmaceuticals US, discusses his vision for creating an organization that is fueled by innovation. PV: How do you define innovation and what was your vision for reshaping of the pharmaceutical division of Novartis in ...
By Fabrice Chouraqui • Jan. 1, 2020